ArticleJCO precision oncology2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.
Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Precision Medicine and Artificial Intelligence in Next-Generation Cancer Surgery: A Comprehensive Analysis of Clinical Applications, Therapeutic Outcomes, and Implementation Strategies.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.JCO precision oncology · 2023Pooled it
- What Genetics Can Do for Oncological Imaging: A Systematic Review of the Genetic Validation Data Used in Radiomics Studies.International journal of molecular sciences · 2022Pooled it
- A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.The oncologist · 2026Trial
- Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.Signal transduction and targeted therapy · 2026Trial
- Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.Journal of translational medicine · 2022Trial
- Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.Genome medicine · 2021Trial
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.Journal of the National Cancer Institute · 2020Trial
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.Nature medicine · 2019Trial
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.Nature medicine · 2019Trial
- A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.Nature communications · 2026Article
- Genomic Therapy Matching in Rare and Refractory Cancers.JAMA oncology · 2026Article
- Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.NPJ precision oncology · 2026Article
- Integrated Molecular and Functional Characterization of Cervical Small-Cell Neuroendocrine Carcinoma Using a 3D Organoid Model.International journal of molecular sciences · 2026Article
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Observational
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
- From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology.Targeted oncology · 2025Article
- Article
- Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region.Diagnostics (Basel, Switzerland) · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
purposeGenomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched targeted therapy (MTT) when available. PATIENTS AND
methodsPatients with advanced cancer who underwent tumor genomic analyses were treated with MTT when available.
resultsOverall, 1,179 (82.1%) of 1,436 patients had one or more alterations (median age, 59.7 years; men, 41.2%); 637 had one or more actionable aberrations and were treated with MTT (n = 390) or non-MTT (n = 247). Patients who were treated with MTT had higher rates of complete and partial response (11%
conclusionOur results support the use of genomic matching. Subset analyses indicate that matching patients who harbor a PI3K and mitogen-activated protein kinase pathway alteration to only a PI3K pathway inhibitor does not improve outcome. We have initiated IMPACT2, a randomized trial to compare treatment with and without genomic selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.